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Objectives. Breast cancer is one of the major cancers in Chinese women. European Organization for Research and Treatment
of Cancer Quality of Life Questionnaires (EORTC QLQ-C30 and QLQ-BR23) are now the most common and well developed
instruments assessing the health-related quality of life (HRQOL) of breast cancer patients internationally, whereas there are
relatively few Chinese studies. This study has two aims: to investigate the HRQOL and explore which dimensions of HRQOL
play more important roles in breast cancer patients’ overall quality of life in China and to explore the latent factor structure and
the potential complementary relationship between these two EORTC questionnaires.Methods.This cross-sectional and descriptive
study was performed from October 2014 to February 2015 in Qingdao Municipal Hospital, China. A total of 621 women breast
cancer patients were enrolled. EOTRC QLQ-C30 and QLQ-BR23 were used to evaluate the HRQOL of the participants. The
nonparametric test, multiple linear regression, and exploratory factor analysis (EFA) were the main statistical methods we used.
Results. 608 participants completed the questionnaires with a response rate of 97.9%. The mean age of the participants was 48.0
years (SD=9.6). About 33% were illiterate or only finished primary school education. Almost half participants (47.4%) only adopted
chemotherapy. HRQOL was significantly different with regard to patients’ social-demographic and clinical characteristics. Age,
residence, educational level, employment status, and TNM stage were five significant predictors for global health status. Pain,
dyspnea, sexual enjoyment, and systemic therapy side-effect were main subscales which had a significant impact on the global
health status for patients in different TNM stage. The EFA result suggested that QLQ-C30 and QLQ-BR23 were complementary
questionnaires.Conclusions.TheEORTCQLQ-C30 andQLQ-BR23 questionnaires provide complementary information regarding
breast cancer patients’ HRQOL, and depending on the different cancer staging functional/symptom scales which significantly
contributed to the overall HRQOL differed.
1. Introduction
Breast cancer is the second most common cancer in the
world and by far the most frequent cancer among women
with an estimated 1.67 million new cancer cases diagnosed
in 2012 (25% of all cancers), and it ranks as the fifth cause of
death from cancer overall (522,000 deaths) [1]. In 2013, breast
cancer is the most prevalent malignant cancer and the fifth
leading cause of cancer death in Chinese women [2, 3]. It has
also been predicted by the International Agency for Research
on Cancer that in 2020 the incidence and mortality of breast
cancer inChinawould be 215,800 and 57,500, respectively [4].
Patient reported outcomesmeasures (PROMs), especially
health-related quality of life (HRQOL) instruments, have
increasingly been collected in randomised controlled trials
(RCTs) to inform patient-centered care, clinical decision-
making, and health policy or reimbursement decisions [5,
6]. Compared with the traditional assessment of clinical
outcomes, HRQOL information plays an important role
in breast cancer research [7]. Being diagnosed and living
with breast cancer are a very stressful experience that may
negatively affect multiple aspects of an individual’s HRQOL
and can have a long-term effect on HRQOL after treatment
[8–10].
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Along with the increasing number of breast cancer
patients and the longer survival due to early detection pro-
grams and advancement in medical technology, accurately
assessing HRQOL of breast cancer patients is crucial [11, 12].
By far, one of the most popular cancer-specific HRQOL
instruments is the European Organization for Research
and Treatment (EORTC) Quality of Life Questionnaire-
C30 (QLQ-C30) [13]. The QLQ-C30 also has additional
modules which can be used to address aspects which are of
particular importance to patients with specific cancers. The
breast cancer-specific module QLQ-BR23, a supplement to
the general cancer questionnaire QLQ-C30, was developed to
identify unique concerns to breast cancer patients [14].
Internationally, there are several studies assessing the
HRQOL among breast cancer patients using the EORTC
QLQ-C30 and QLQ-BR23 [7, 15–17]. The simplified Chinese
versions of the above two questionnaires, which are com-
monly referred to as EORTCQLQ-BR53, have been validated
inmainland China, demonstrating the validity, reliability and
responsiveness in breast cancer patients [18, 19]. Although the
QLQ-BR23 was developed to be used as an extension of the
QLQ-C30; the literature is mixed as to whether to use both or
either one of them in breast cancer patients [20].
The aims of this study are twofold: firstly, to explore
which dimensions of HRQOL play more important roles
in breast cancer patients’ overall quality of life in China
and, secondly, to explore the latent factor structure and
the potential complementary relationship between these two
EORTC questionnaires in breast cancer patients.
2. Patients and Methods
2.1. Patients. Participants were recruited from women breast
cancer patients who have been treated in QingdaoMunicipal
Hospital, China, between October 2014 and February 2015.
A total of 621 female breast cancer patients who underwent
inpatient treatment from the oncology wards were inter-
viewed. Patients clearly diagnosed with breast cancer and
more than 18 years old were selected as an inclusion criterion.
The exclusion criterionswere as follows: (1) being unwilling to
give an informed consent or (2) being unable to understand
the questionnaires, or (3) being combined with other serious
chronic diseases, such as cardiovascular or cerebrovascular
diseases, psychosis, or (4) being younger than 18 years old
at the time of the survey. Informed consent was obtained
from all participants after a detailed explanation of the
study. Ethical approval was obtained from the Ethics Review
Board of the School of Public Health, Shandong University
(Reference No. 20131002), and the research adhered to the
tenets of the Declaration of Helsinki.
2.2. Tools and Measures. The participants were interviewed
face to face one day prior to discharge. During the inter-
view, information on sociodemographic characteristics of
the participants was obtained, while the clinical information
was collected by the interviewer based on the medical
records. The HRQOL was self-assessed by each patient using
the simplified Chinese version of the EORTC QLQ-BR53
questionnaires.
The EORTC QLQ-C30 is a reliable and valid ques-
tionnaire developed to assess the quality of life (QOL) of
cancer patients, which has been translated and validated in
over 100 languages and is used in more than 3,000 studies
worldwide [21]. QLQ-C30 consists of 30 items (coded Q1-
Q30), including a global health status (GHS)/QOL scale, five
multi-item functional subscales (physical /role /emotional
/cognitive /social functioning), and several single/multi-item
symptomatic subscales (fatigue /nausea and vomiting /pain
/dyspnoea /insomnia /appetite loss /constipation /diarrhea
/financial difficulties) [13]. The EORTC QLQ-BR23 (coded
BR1-BR23), a 23-item breast cancer-specific supplemental
module, is meant for use among patients varying in disease
stage and treatment modality. The module incorporates five
multi-item scales to assess systemic therapy side-effects,
arm symptoms, breast symptoms, body image, and sexual
functioning. In addition, three single items assess sexual
enjoyment, hair loss, and future perspective [14].
The QLQ-BR53 is rated on a four-level Likert scales
response system, from 1 “not at all” to 4 “very much.” Except
for the GHS items, Q29 and Q30, a seven-level Likert scale
is used, from 1 “very poor” to 7 “excellent.” The time frame
of the questionnaires is “during the past week,” except for
the sexual functioning and sexual enjoyment (“during the
past four weeks”). Scales raw scores are calculated by aver-
aging items within scales. The raw score of the participants’
responses are then linearly transformed to a 0–100 score
according to the official EORTC scoring manual [22]. The
score ranges from 0 to 100, with a higher score indicating a
better quality of life for the functioning andGHS but a poorer
quality of life for severe symptomatic problems. The GHS
scale was used as the overall summary measure, where a high
score represents a high overall quality of life.The level of self-
assessed GHS helps in predicting survival, which is especially
important among survivors to improve the QOL.
For all scales, the raw score, RS, is the mean of the
component items:
Raw Score = RS = (I1 + I2 + ⋅ ⋅ ⋅ + In)
n
. (1)
Standard Score, SS, for global health status/functional
scales are calculated as
SS = {1 − (RS − 1)
range
} × 100. (2)
And SS for symptom scales/items are calculated as
SS = {(RS − 1)
range
} × 100. (3)
2.3. Statistical Analysis. Descriptive statistics was used to
summarize sociodemographic and clinical characteristics of
the participants. Normality tests were carried out for QOL
scores. As all QOL scores were non-normally distributed,
nonparametric tests (i.e.,Mann–WhitneyU test andKruskal-
Wallis test) were performed to determine whether differences
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in the mean score of QOL across sociodemographic and
clinical parameters of the participants were significant. Dif-
ferences were considered significant if p value was equal to or
less than 0.05.
Regarding aim 1, step-wise multiple linear regression was
conducted to investigate the statistically significant predictors
associated with global QOL. Regarding aim 2, the Spearman
rank correlation coefficients between QLQ-C30 and QLQ-
BR23 subscales were firstly calculated, with correlation coeffi-
cient> 0.5 indicating amoderate association and a value< 0.5
representing a weak association [23]. Next, the latent factor
structure was explored by using an exploratory factor analysis
(EFA). The number of factors was extracted according to
the eigenvalue (i.e., eigenvalue >1). To account for potential
correlations among factors, rotation was performed using an
oblique Promax method. Data were analyzed using a SPSS
software package (SPSS version 22.0 Inc., Chicago, IL, USA).
3. Results
3.1. Sociodemographic and Clinical Characteristics. Six hun-
dred and twenty-one women patients with confirmed diag-
nosis of breast cancer were interviewed. Of the total 621
patients, 13 were deleted due to incomplete answers. Finally,
a valid sample of 608 patients (97.9%) was analyzed. The full
sample sociodemographic and clinical characteristics were
presented in Table 1.
3.2. QOL Scores byQLQ-C30 andQLQ-BR23. Table 2 showed
the detailed QOL scores measured by QLQ-C30 and QLQ-
BR23. The mean ± standard deviation (SD) score of GHS
was 53.8±14.7. Among functional scales, more severe impair-
ments were observed among future perspective (51.5±31.4),
body image (64.9±25.0), and social functioning (69.9±24.6).
Regarding symptom scales, more severe impairments were
observed on insomnia (31.4±24.4), fatigue (34.0±18.1), finan-
cial difficulties (34.6±28.7), andupset by hair loss (38.6±30.3).
3.3. QOL Scores by Characteristics of the Participants and
the Predictors of Global Health Status (GHS)/QOL. Table 3
presented main differences of QOL scores across clinical
characteristics (while more detailed data about QOL by
sociodemographic and clinical characteristics can be found
in the supplementary materials (available here)). There were
no significant differences for both QLQ-C30 and QLQ-BR23
functional scales among patients in different TNM stage.
While significant differences were observed in QLQ-C30
symptom scales (including fatigue, nausea and vomiting,
pain, dyspnea, appetite loss, and constipation). Patients who
received chemotherapy only had lower scores in GHS as well
as symptom scales while higher scores in functional scales
than those that adopted other types of treatment.
Table 4 showed that among patient characteristics (Panel
A), age, residence, educational level, employment status, and
TNM stage were five statistically significant predictors for
GHS. However, when further investigating the factors by
the TNM stages, it can be seen that, in early stages (i.e.,
TNMstages 0-II), agewas insignificant andmarital statuswas
significant, while, in advanced stages (i.e., TNM stages III-
IV), marital status and employment status were insignificant.
The significant functional/symptom subscales which
impacted on the global health status were reported in Panels
B and C in Table 4. According to the different stages of cancer
progressing, the significant scales in QLQ-C30 differed. In
early stages, pain, dyspnea, and fatigue were significant,
while, in advanced stages, role functioning, cognitive func-
tioning, emotional functioning, nausea and vomiting, pain,
and dyspnea were all significantly impacted on the global
health status. Among the QLQ-BR23 scales, the same pattern
of significant predictors was identified between different
stages of breast cancer patients.
3.4. Spearman’s Rank Correlation and EFA Factor Structure
of QLQ-C30 and QLQ-BR23. Table 5 showed Spearman’s
rank correlation coefficients between QLQ-C30 and QLQ-
BR23 scales. Generally speaking the correlations were weak,
with the highest correlation coefficient of 0.428 (between
“financial difficulties” in QLQ-C30 and “systemic therapy
side-effects” in QLQ-BR23).
The exploratory factor analysis result was reported in
Table 6. A total of 10 factors, which explained 61% of the vari-
ance, were extracted based on the eigenvalues (eigenvalues>1;
Kaiser-Meyer-Olkin test=0.939; all communalities >0.34). As
can be seen, QLQ-C30 and QLQ-BR23 items are attached to
different latent factors, with the only exception observed in
the third and fourth factor.
4. Discussion
By conducting a cross-sectional survey with 608 breast
cancer patients, this study investigated two important issues
that have not been explored in mainland China: what the
important functional/symptom scales as well as patient char-
acteristics that contributed to the overall quality of life of
breast cancer patients are and whether those scales differ
by different stages of cancer progressing and, furthermore,
whether each of the QLQ-C30 and QLQ-BR23 provides
unique information for the breast cancer patients and thus
serves as a complementary measure to each other.
The breast cancer patients in our study had a mean GHS
score of 53.8 (SD=14.7), lower than the EORTC QLQ-C30
Reference Values (mean=61.8, SD=24.6) [24], which might
be explained by the larger proportion of patients receiving
chemotherapy only as the type of treatment in our study
(47.4%). It was reported that patients receiving chemotherapy
might experience several side-effects that negatively affected
their QOL [25].This was confirmed in our study that patients
received chemotherapy reported worse GHS comparing with
those undergoing other types of treatment.
In our study, younger patients with a lower educational
level reported significantly lower scores in sexual functioning
and sexual enjoyment. In addition, the scores of sexual
functioning and sexual enjoyment were pretty high com-
paring with similar researches [11, 26]. The findings were
not consistent with the previous ones that disrupted sexual
functioning or unsatisfactory sexual life was related to poorer
HRQOL at younger age, treatment with chemotherapy, and
4 BioMed Research International
Table 1: Sociodemographic and clinical characteristics of the participants (n=608).


















Illiteracy or Primary school 200 32.9
Secondary school 128 21.1
High school/technical secondary school 131 21.5
University degree and above 149 24.5






















Chemotherapy only 288 47.4
Others 320 52.6
Note:
TNM: tumor, node, and metastases classification of malignant tumors.
Exchange rate: according to the Organization for Economic Cooperation and Development (OECD) data (https://data.oecd.org/conversion/exchange-
rates.htm), the average annual exchange rate between US$ and CNY in 2014 was US$1 = CNY 6.143, and in 2015 it was US$1 = CNY 6.227.
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Table 2: Quality of life scores for all participants (n=608).
EORTC Item Mean score SD Median
Panel A: QLQ-C30 Questionnaire
Global Health Status 53.8 14.7 50.0
Functional Scales
Physical functioning 75.5 17.2 80.0
Role functioning 77.4 25.5 83.3
Emotional functioning 74.2 19.7 75.0
Cognitive functioning 76.9 19.5 83.3
Social functioning 69.9 24.6 66.7
Symptom Scales
Fatigue 34.0 18.1 33.3
Nausea and vomiting 19.0 21.5 16.7
Diarrhoea 10.4 18.9 0.0
Financial difficulties 34.6 28.7 33.3
Pain 28.9 19.9 33.3
Dyspnoea 17.2 22.2 0.0
Insomnia 31.4 24.4 33.3
Appetite loss 24.1 25.3 33.3
Constipation 24.6 26.4 33.3
Panel B: QLQ-BR23 Questionnaire
Functional Scales
Body image 64.9 25.0 66.7
Sexual functioning 89.0 15.9 100.0
Future perspective 51.5 31.4 66.7
Sexual enjoyment 88.3 19.6 100.0
Symptom Scales
Systemic therapy side effects 24.7 16.9 23.8
Breast symptoms 17.1 19.8 8.3
Arm symptoms 20.2 19.6 16.7
Upset by hair loss 38.6 30.3 33.3
SD, standard deviation
emotional distress [27–29].Theremight be an overestimation
and the main potential reason may be the unique culture
background. Sexuality is considered a private topic and is
not openly discussed in public in China [30]. Thus, Chinese
women are more conservative about the sex-related topics;
the older or the lower-educated patients are more likely to
avoid answering these questions or choose a random answer.
As a disease closely related to women’s identities, breast
cancer affected the perception of sexuality and their own
personal image [29].Therefore,more attention should be paid
to Chinese women with breast cancer on sexual problems.
Age, residence, educational level, employment status, and
TNM stage were five significant predictors for overall quality
of life according to the result of multiple linear regression.
According to Wong-Kim et al., after being diagnosed with
breast cancer, the Chinese women were more concerned
about survival and may put a greater emphasis on recuper-
ating from their illness rather than worrying about body
image and their marital relationship. But, for traditional
Chinese women, they did not want to burden their families
with their deteriorating health [31]. What is more, patients
with early breast cancer may be concerned about premature
menopause leading to loss of fertility, recurrence, body image,
and sexuality [32, 33], which could have a negative effect
on their overall quality of life. Generally, better GHS scores
were found in patients with stable job security, who were
more likely to seek access to information and resources for
problem solving. And they could be more compliant with
the therapeutic regime because they had little problem in
financial difficulties and felt more secure. However, when
further investigating the factors by TNM stages, age was
insignificant for early stage patients (TNM stages 0–II), and
marital and employment status were insignificant for patients
in advanced stages (TNM stages III-IV). The certain reasons
were not clear at present, which remains to be discussed.
Qualitative research can be considered to be applied to
investigate the potential reasons in the future.
According to the different stages of cancer progress-
ing, the significant subscales differed. For all patients, an
increased level of systemic therapy side-effect was linked
to a decrease on GHS score. Increased levels of pain and
fatigue were associated with a 0.107 and 0.212 GHS score
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Table 4: Final model of predictors for Global Health Status scores.
GHS of all
participants
GHS of patients in
TNM Stage 0–II
GHS of patients in
TNM Stage III-IV
Coefficient (SE) Coefficient (SE) Coefficient (SE)
Panel A: Patient characteristics
(Constant) 87.720(5.150)∗∗ 102.608(6.136)∗∗ 64.272(7.553)∗∗
Age -0.146(0.053)∗ -0.039(-0.774) -0.183(0.071)∗
Residence (ref: urban)
rural 5.454(1.220)∗∗ 5.848(1.834)∗ 2.920(1.365)∗
Marital status (ref: single)
Married -0.047(-1.295) -15.586(4.604)∗ -0.001(-0.015)
Divorced/widow -0.023(-0.660) -14.775(5.079)∗ -0.025(-0.506)
Educational level (ref: illiteracy /primary school)
Secondary school -0.020(-0.582) -0.034(-0.673) 0.024(0.509)
High school/technical secondary school 0.043(1.098) 0.085(1.461) 0.046(0.906)
university degree and above 6.432(1.275)∗∗ 5.418(1.920)∗ 8.956(1.699)∗∗
Employment status (ref: urban employee)
peasants -4.947(1.395)∗∗ -4.515(1.898)∗ -0.099(-1.877)
unemployment -4.336(1.984)∗ -0.092(-1.791) -0.029(-0.647)
others -0.037(-1.134) -0.019(-0.395) -0.010(-0.222)
TNM Stage (ref: 0-II)
III-IV -1.912(0.952)∗ —— ——
Panel B: QLQ-C30 scales
Role functioning 0.081(0.028)∗ 0.050(0.711) 0.119(0.039)∗
Cognitive functioning 0.077(1.520) 0.035(0.510) 0.211(0.058)∗∗
Emotional functioning -0.066(-1.392) -0.047(-0.720) -0.131(0.056)∗
Nausea and vomiting 0.046(1.017) -0.056(-0.874) 0.099(0.042)∗
Pain -0.125(0.038)∗ -0.107(0.050)∗ -0.140(0.055)∗
Dyspnoea 0.128 (0.027)∗∗ 0.123(0.042)∗ 0.104(0.035)∗
Fatigue -0.135(0.043)∗ -0.212(0.058)∗∗ -0.130(-1.771)
insomnia -0.049(0.023)∗ -0.037(-0.670) -0.082(-1.507)
Panel C: QLQ-BR23 scales
Sexual enjoyment -0.230(0.027)∗∗ -0.273(0.041)∗∗ -0.194(0.035)∗∗
systemic therapy side effect -0.213(0.042)∗∗ -0.144(0.050)∗ -0.185(0.055)∗
Arm symptoms 0.078(0.034)∗ 0.107(1.711) 0.120(1.912)
Body image -0.053(0.025)∗ -0.075(-1.223) -0.092(-1.609)
Note: stepwise regression was applied in the multiple linear regression analysis; a constant was included in each model.
SE, Standard Error; ∗∗ and ∗ indicate P < 0.01 and P < 0.05, respectively.
decreased for early stage patients, and increased levels of
role and cognitive functioning were associated with a 0.119
and 0.211 GHS score increased for advanced stage patients.
These findings were consistent with former studies that
treatment side-effects (even those of lower grade)may induce
symptoms such as nausea and vomiting, pain, and fatigue,
which are not life-threatening but can adversely impact
patients’ well-being and are associated with worse HRQOL
[34]. While an increased level of sexual enjoyment associated
with a decrease on GHS score and the aggravation of dyspnea
associated with an increase on GHS score were inconsis-
tent with our common sense. The subjective perception of
HRQOLmight not necessarily be in accordance with relevant
clinical factors [35]. Patients’ expectation might change with
time and psychological response to breast cancer might be
independent of cancer stage [36]. If a person is confronting
an incurable condition their values will shift and patients
certainly assign different values to hypothetical health states
than outsiders [20]. Therefore, more attention should be
paid to improve patients’ HRQOL through dealing with the
particular impaired function or symptom for it has been quite
difficult to extend lifespan for the advanced breast cancers or
the long-term survivors.
This study also investigated the complementary roles
between two EORTC questionnaires in breast cancer. The
correlation and factor analysis have been used to confirm the
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construct and criterion-related validity of the simplified Chi-
nese version of the QLQ-BR53; however, the factor analyses
were applied separately to QLQ-C30 and QLQ-BR23 [18, 19].
In our study, Spearman’s rank correlation and an EFA analysis
were used to assess the degree of conceptual overlap between
QLQ-C30 andQLQ-BR23.The results showed that therewere
only weak correlations between the two QOL instruments of
EORTC QLQ-C30 and QLQ-BR23. The EFA results showed
cumulative contribution rates > 61%, indicating a good
extraction effect. Ten common factors extracted were not
completely conformed to the theory structure of the EOTRC
QLQ-BR53 scales, but the EFA results mostly confirmed the
original scoring algorithm. Among 10 latent factors, only
factors 3 and 4 were composed of both QLQ-C30 items and
one QLQ-BR23 item, further confirming a complementary
role between these two questionnaires.
This study has two main limitations. Firstly, the patients
were recruited from eastern China and the conclusions may
not be applicable to the whole Chinese populations. Second,
this was a cross-sectional study. It will be important to further
assess the changes on HRQOL using a longitudinal survey
design.
In conclusion, clinical characteristics are relevant factors
influencing the QOL of women breast cancer patients in
eastern China. Age, residence, educational level, employment
status, and TNM stage were five significant predictors for
GHS. Pain, dyspnea, sexual enjoyment, and systemic therapy
side-effect were main subscales which had a significant
impact on the global health status for all patients. As
complementary questionnaires, it is recommended that the
EORTCQLQ-C30 andQLQ-BR23 should be applied to assess
HRQOL at the same time. The results of this study enriched
our understanding of using EORTC QLQ-C30 and QLQ-
BR23 questionnaires in China.
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More detailed data about quality of life scores by sociode-
mographic and clinical characteristics of the participants
were displayed in the supplementary materials. Differences
in the mean score of quality of life across sociodemographic
and clinical parameters of the participants were considered
significant if p value was equal to or less than 0.05. Table S1:
quality of life scores by age, residence (house locality), and
marital status; Table S2: quality of life scores by educational
level and medical security; Table S3: quality of life scores
by annual household income and disease duration; Table S4:
quality of life scores by metastatic breast cancer state (State
M) and menopausal status. (Supplementary Materials)
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